Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We are also pleased with the progress with our robust development pipeline across solid tumor cancers |
| We are confident in our ability to deliver a successful commercial launch |
| In addition, our Phase 3 TILVANCE-301 trial continues with a strong momentum in several countries to support regulatory submissions in frontline advanced melanoma |
| These are consistent with approved CAR T product with the benefit of increased speed resulting from both our preparation and the ATC's experience |
| The strength of this label also reflects a best case scenario with strong efficacy data from pivotal Cohort 4 as well as pull Cohorts 2 and 4 |
| launch, we are seeing strong demand and momentum for AMTAGVI |
| The patients in process for AMTAGVI is a very encouraging update given that we're just a week and a half in |
| Global site activation and patient enrollment continue its strong momentum in the US, Europe, Australia, Canada and additional countries |
| We are well positioned to execute on our regulatory pipeline, manufacturing commercial launch activities to remain the global leader in TIL cell therapy |
| This is a testament to the high unmet medical need and the great segment around this new therapy as well as our commercial manufacturing readiness |
| Build-out of additional clean rooms within the existing shelf space at iCDC can significantly increase capacity to over 5,000 patients annually over the next few years |
| And as we expand and as we grow, I think we'll be able to manage that even more tightly as we learn a little bit more right now about how the sites perform and who's doing the best here |
| We are also pleased with the initial market access and inpatient reimbursement trends for Amtagv |
| And we're very happy with the fact that the FDA gave us a lot of space to be able to manufacture |
| About three quarters of our payer mix has strong coverage in reimbursement |
| FDA's recent approval of AMTAGVI, the first one-time T cell therapy for solid tumor |
| It takes a large and coordinated effort to deliver this type of first-in-class category therapy to patients, and this achievement is a testament to the unwavering commitment expertise and collaborative efforts of many |
| Iovance is the leader in T cell therapy, including next-generation approaches that have the potential to optimize outcomes for patients |
| launch of Amtagvi as well as the sales of Proleukin used in conjunction with the Amtagvi treatment regimen are expected to drive significant revenue in the second half of 2024 and into 2025 and beyond |
| So, we're confident that we gave them what they needed them being the FDA, in this case in order to see what our plans are |
| This means that we can increase near-term capacity through increased staffing without requiring additional capacity authorizations |
| MA has been very cooperative, very interesting in getting this drug in patients |
| I want to acknowledge our strong cross-functional teams who have worked tirelessly to ensure our launch, readiness and execution |
| What we're seeing here, I think, is a pent-up demand and real excitement for the AMTAGVI launch |
| We build their service line and make sure that they're successful in the treatment |
| But what we want to do is make sure that with these top centers, we reinforce success |
| There is a strong level of ATC commitment with 30 onboard today |
| Our mission is to remain the global leader in innovating, developing and delivering health therapies, and we have now planned a firm stake in the ground as the pioneers of the first commercial TIL therapy |
| 2024 is already off to an incredible start for Iovance |
| I would also like to thank our shareholders and covering analysts for their support; and lastly, I want to thank our exceptional Iovance team, we could not be here without their cross-functional efforts and our collective steadfast commitment to following the science |
| Statement |
|---|
| Sorry, we're having some technical difficulties there |
| We're just having a difficult time hearing the analysts |
| Net loss for the fourth quarter ended December 31, 2023, was $116.4 million or $0.45 per share compared to a net loss of $105.3 million or $0.64 per share for the fourth quarter ended December 31, 2022 |
| Would love to know, should we just be expecting longer follow-up? Will we have more patients and for that update? And related to that, you guys have other trials that are ongoing, could we be -- could we get additional clinical data from either 4001 or one of the other studies that's ongoing this year? Fred Vogt So Rene, we had a technical issue here |
| As Fred pointed out, there has been some quick movement because the sense of urgency at these ATCs |
| Net loss for the year ended December 31, 2023, was $444 million or $1.89 per share compared to a net loss of $395.9 million or $2.49 per share for the year ended December 31, 2022 |
| Correct me if I'm wrong |
| Fred Vogt And operator, can you confirm that you can hear me just because of the technical difficulties |
| Our results may differ materially from those projected during today's call |
| So, that also hasn't changed |
| And then I guess the second part of the question, Friedrich, could you -- that won't keep you clearly at least here |
Please consider a small donation if you think this website provides you with relevant information